Tamper-Resistant Opioid Formulations in the Treatment of Acute Pain
- First Online:
- 577 Downloads
Pain—including acute or persistent acute pain—is a common condition that is increasingly being treated with opioids in the United States. The acute pain treatment setting may represent a key target for addressing the growing epidemic of prescription drug abuse occurring hand in hand with the rise in opioid prescribing. Balancing the needs of pain treatment with abuse prevention can be challenging for clinicians.
This article identified efforts to balance opioid abuse risks with opioid availability through the extensive experience of the author in this field. In addition, PubMed literature searches using terms such as “prescription opioid abuse”, “abuse-deterrent opioids”, and “tamper-resistant opioids”; and inspection of the bibliographies of relevant articles were used to identify relevant sources.
These multifaceted efforts have included: improving assessment of patient risk for drug misuse, abuse, or diversion; funding of and encouraging referral to addiction treatment programs; access to and widespread use of prescription monitoring programs (PMPs); public knowledge of prescription opioid abuse; proper storage of opioid medications; and development of new formulations designed to resist tampering and deter abuse. This review discusses the problem of prescription opioid abuse and strategies to minimize risk within the context of acute pain treatment, and explores the potential role of tamper-resistant opioid formulations and other abuse deterrence strategies in the area of acute or persistent acute pain management.
In order to stem the tide of prescription opioid abuse and preserve the availability of opioids as a much needed analgesic option, a multifaceted approach that includes tamper-resistant opioid formulations—for chronic or acute pain—along with strategies such as improved patient risk assessment, funding for and referral to addiction treatment programs, greater use of PMPs, and raised awareness of prescription opioid abuse is needed.
KeywordsAcute pain Opioid abuse Opioids Pain Pain medications Tamper-resistant formulations
- 1.US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2006. With chartbook on trends in the health of Americans. Hyattsville: National Center for Health Statistics; 2006. DHHS Publication No. 2006-1232. http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed January 10, 2013.
- 6.US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Prescription painkiller overdoses in the US. November, 2011. http://www.cdc.gov/VitalSigns/pdf/2011-11-vitalsigns.pdf. Accessed December 9, 2012.
- 9.Cai R, Crane E, Poneleit K, Paulozzi L. Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2010;59:705–9.Google Scholar
- 10.Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60:1487–92.Google Scholar
- 11.Paulozzi L, Baldwin G, Franklin G, et al. CDC grand rounds: prescription drug overdoses—a US epidemic. MMWR Morb Mortal Wkly Rep. 2012;61:10–3.Google Scholar
- 14.The Joint Commission on Accreditation of Healthcare Organizations, The National Pharmaceutical Council. Pain: current understanding of assessment, management and treatments. Washington, DC: The National Pharmaceutical Council; 2001. http://www.npcnow.org/system/files/research/download/Pain-Current-Understanding-of-Assessment-Management-and-Treatments.pdf. Accessed January 16, 2014.
- 16.Dart R. RADARS® System Sixth Annual Meeting. April 24, 2012. http://www.radars.org/Portals/1/01_DartR_RADARS_System_Annual_Meeting_2012_distribution_20120502.pdf. Accessed December 9, 2012.
- 17.Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System. RADARS® System data indicate immediate release opioids responsible for higher proportion of misuse, abuse and diversion than extended release opioids. RADARS Syst News. 2009;4:1–4.Google Scholar
- 18.US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville: Substance Abuse and Mental Health Services Administration; September 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf. Accessed January 10, 2013.
- 19.Sproule B, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician. 2009;55:68–9.e5.Google Scholar
- 24.Governale L. Outpatient prescription opioid utilization in the U.S., years 2000–2009. Silver Spring: U.S. Food and Drug Administration; July 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM220950.pdf. Accessed August 1, 2012.
- 25.Tufts Health Care Institute. The role of dentists in preventing opioid abuse. Tufts Health Care Institute Program on Opioid Risk Management. 12th Summit Meeting. Executive Summary. Boston: Tufts Health Care Institute; 2010. http://www.thci.org/opioid/mar10docs/executivesummary.pdf Accessed January 10, 2013.
- 33.Oxecta™ (oxycodone HCl, USP) tablets for oral use only—CII [package insert]. Palatine: Acura Pharmaceuticals Inc.; 2013. http://labeling.pfizer.com/showlabeling.aspx?id=620. Accessed January 16, 2014.
- 34.Schoedel KA, Rolleri RL, Faulknor JY, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag. 2012;8:315–27.PubMedCrossRefGoogle Scholar
- 35.Devarakonda K, Morton T, Giuliani M, et al. Single-dose pharmacokinetics of 1 and 2 tablets of MNK-795 controlled-release oxycodone/acetaminophen tablets (CR OC/APAP) compared with immediate-release oxycodone and acetaminophen. Presented at: PAINWeek; September 4–7, 2013; Las Vegas, NV. Poster 19.Google Scholar
- 36.Mallinckrodt Pharmaceuticals Announces Positive Phase 3 Efficacy Results for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination [press release]. Sept. 5, 2013. Las Vegas: Mallinckrodt Pharmaceuticals. http://news.mallinckrodt.com/press-release/company/mallinckrodt-pharmaceuticals-announces-positive-phase-3-efficacy-results-mnk-7. Accessed January 14, 2014.
- 37.Singla N, Barrett T, Sisk L, Kostenbader K, Young J, Giuliani M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, IR and ER combination analgesic for acute pain. Curr Med Res Opin. 2014. (Epub ahead of print).Google Scholar
- 38.Morton T, Kostenbader K, Montgomery J, et al. Comparison of subjective drug effects of orally administered MNK-795 controlled-release oxycodone/acetaminophen tablets (CR OC/APAP) vs immediate-release oxycodone/acetaminophen tablets in recreational users of prescription opioids. Presented at: PAINWeek; September 4–7, 2013; Las Vegas, NV. Poster 69.Google Scholar
- 39.Pande P, Hines JW, Brogan P. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone ER). Presented at: American Pain Society 30th Annual Scientific Meeting; May 19–21, 2011; Austin, TX. Poster 331.Google Scholar
- 42.Szalavitz M. Abuse-proof OxyContin pushes addicts to heroin and other opioids, survey finds. Time Web site. July 12, 2012. http://healthland.time.com/2012/07/12/new-abuse-proof-oxycontin-formula-pushed-addicts-to-heroin-and-other-opioids-survey-finds/. Accessed January 10, 2013.
- 43.Leinwand Leger D. Opana abuse in USA overtakes OxyContin. USA Today Web site. July 10, 2012. http://usatoday30.usatoday.com/news/nation/story/2012-07-10/opana-painkiller-addiction/56137086/1. Accessed January 10, 2013.
- 46.Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131–46.PubMedCrossRefGoogle Scholar
- 48.Center for Lawful Access and Abuse Deterrence. National prescription drug abuse prevention strategy: 2011–2012 update. Arlington, VA: Center for Lawful Access and Abuse Deterrence; 2011. http://www.claad.org/downloads/CLAAD_Strategy2011_v3.pdf. Accessed January 14, 2013.
- 50.Cordy C, Kelly P. Patterns of prescribing—the Rhode Island prescription monitoring program. R I Med J. 2013;96:36–7.Google Scholar
- 52.United States General Accounting Office. Prescription drugs: state monitoring programs provide useful tool to reduce diversion. May 2002. GAO-02-634. http://www.gao.gov/assets/240/234687.pdf. Accessed January 16, 2014.
- 57.Executive Office of the President of the United States. Epidemic: responding to America’s prescription drug abuse crisis. Washington, DC: Executive Office of the President of the United States; 2011. http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf. Accessed January 14, 2013.
- 58.US Department of Health and Human Services, US Food and Drug Administration. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. Silver Spring: US Food and Drug Administration; July 2012. http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed January 14, 2013.